

Budesolv




The first low-dose intranasal, preservative-free corticosteroid with strong symptom relief after first dose for treating allergic rhinitis

Budesolv is a nasal spray containing the corticosteroid budesonide solubilized with Marinomed's proprietary Marinosolv® solubilization technology. It is intended to treat allergic rhinitis and has met all endpoints in a phase III clinical trial¹.


Benefits

- Solution instead of suspension of API
- Highly increased bioavailability
- Fast onset of action after first dose
- Low dose application (~15% of originator)
- Preservative-free formulation
- Easy to use - no shaking, high-precision dosing
- Manufacturing - aseptic large-scale production

Primary and secondary endpoints met in phase III clinical trial¹



Clinical phase III data¹



Faster onset of action of Budesolv versus Placebo and marketed comparator on day one after first dose


—●— Budesolv —●— Placebo —●— Rhinocort® Aqua 64

*TNSS = total nasal symptom score (runny nose, itchy nose, congestion, sneezing)

Budesolv is non-inferior to the originator with a strongly reduced dose (~85%) of Budesonide and in addition, it is the first intranasal steroid formulation with immediate symptom relief

¹Ziegelmayer P, Schmutz R, Lemell P, et al. Fast effectiveness of a solubilized low-dose budesonide nasal spray in allergic rhinitis. Clin Exp Allergy. 2020; 50: 1065–1077. <https://doi.org/10.1111/cea.13691>

Marinosolv® Technology Platform



Marinosolv® Benefits

- Solubilization of poorly water-soluble compounds
- Significantly increases bioavailability
- Allows dose reduction & faster onset of action
- Reduces pharmaceutical compounds in wastewater
- Clinically validated & patent protected
- Suitable for sensitive tissues such as eyes and nose

**~85%
dose
reduction**

Partnering opportunities

- Classical license deal with downpayment, milestones and royalties
- Patent protected until 2043
- Possible line extensions:
 - **Nasal spray combination products with anti-histamines** - Chronic rhinosinusitis
 - **Inhalation** - Asthma, COPD

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with globally marketed therapeutics and a growing development pipeline. The Company focuses on the development of innovative products based on two patent-protected technology platforms, Marinosolv® and Carragelose®. Marinomed is listed on the prime market segment of the Vienna Stock Exchange (VSE: MARI).

For more information, please contact our Business Development team:
E-Mail: bd@marinomed.com
Tel: +43 2262 90300
www.marinomed.com



Follow us on

@Marinomed Biotech AG



@Marinomed_AG



Budesolv

Marinomed Biotech AG, www.marinomed.com
Hovengasse 25, 2100 Korneuburg, Austria